Jfl Life SciencesShare price, financial results, shareholding and management

NSE Emerge · JFLLIFEPharmaceuticals & BiotechnologyListed 8 Sept 2022
jfllifesciences.com ↗Live price on NSE ↗ISIN INE0LA901015 · Lot 6,000 shares · ₹70,800
₹11.80
+4.90% on the day
Close · 6 Nov 2026
Valuation
Market cap
₹39 cr
Stock P/E
6.1peers 21.3
Book value
₹13.9
Price to book
0.85
EV / operating profit
5.1
Market cap to sales
0.30
Returns and growth
ROCE · FY26
18.2%
ROE · FY26
15.0%
ROE, 3-year average
11.6%
Operating margin · FY26
8.9%peers 12.7%
Sales growth, 3 years
45.1%
Profit growth, 3 years
28.7%
Safety
Debt to equity
0.47peers 0.57
Borrowings
₹21.7 cr
Interest cover
5.1×
Cash from business / op. profit
-37%
Debtor days
148
Pledged
0.00%
Ownership and share
Promoter holding
67.47%
Change in promoter holding
0.00 pts
Shareholders
904
52-week high / low
₹15 / ₹9
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.

Jfl Life Sciences share price chart

₹11.80-9.23% 1 year

Close on 6 Nov 2026 · +4.89% on the day · Vol 36,000

Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 6 Nov 2026

1 month
+15.1%
3 months
-13.6%
6 months
+27.6%
1 year
-9.2%
Traded a day, 20 days
₹0.02 cr
Taken for delivery
91%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+60%+54%
3 years, a year+45%+29%

Jfl Life Sciences revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150Sales, FY19: 32 ₹ cr32Net profit, FY19: 0 ₹ cr0FY19Sales, FY20: 30 ₹ cr30Net profit, FY20: 0 ₹ cr0FY20Sales, FY21: 33 ₹ cr33Net profit, FY21: 1 ₹ cr1FY21Sales, FY22: 34 ₹ cr34Net profit, FY22: 3 ₹ cr3FY22Sales, FY23: 43 ₹ cr43Net profit, FY23: 3 ₹ cr3FY23Sales, FY24: 47 ₹ cr47Net profit, FY24: 3 ₹ cr3FY24Sales, FY25: 82 ₹ cr82Net profit, FY25: 4.2 ₹ cr4.2FY25Sales, FY26: 131 ₹ cr131Net profit, FY26: 6.4 ₹ cr6.4FY26
The latest halves, ₹ crore
SalesNet profit
010203040Sales, H2FY25: 33 ₹ cr33Net profit, H2FY25: 0.8 ₹ cr0.8H2FY25

SME companies report every six months.

Jfl Life Sciences half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H2FY25
Sales32.99
Expenses30.25
Operating profit2.74
OPM8.3%
Interest0.55
Depreciation0.51
Profit before tax1.68
Net profit0.80

Jfl Life Sciences profit and loss

Full years to March, FY19 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY19FY20FY21FY22FY23FY24FY25FY26
Sales32303334434782.04131.38
Expenses30283128394273.84119.67
Operating profit1225458.2011.71
OPM4.2%6.0%7.0%16.0%9.0%10.0%10.0%8.9%
Other income0001210.010.07
Interest1112111.082.11
Depreciation0000000.991.08
Exceptional and other items·-1··-1-1··
Profit before tax0014446.148.60
Tax rate28.0%29.0%0.0%25.0%25.0%25.0%32.2%25.6%
Net profit0013334.166.40
EPS ₹1.251.501.500.590.430.501.261.94
Dividend payout0.0%0.0%0.0%0.0%0.0%8.0%0.0%0.0%

The years to FY24 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

Jfl Life Sciences profitability

Margins and returns on capital

Last year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%5%10%15%20%FY19: 4.2%4.2%FY19FY20: 6.0%6.0%FY20FY21: 7.0%7.0%FY21FY22: 16.0%16.0%FY22FY23: 9.0%9.0%FY23FY24: 10.0%10.0%FY24FY25: 10.0%10.0%FY25FY26: 8.9%8.9%FY26
Per cent
FY19FY20FY21FY22FY23FY24FY25FY26
Operating margin4.2%6.0%7.0%16.0%9.0%10.0%10.0%8.9%
Tax rate28.0%29.0%0.0%25.0%25.0%25.0%32.2%25.6%
ROCE·7.2%10.5%23.8%15.2%12.3%15.7%18.2%
ROE·0.0%16.8%34.3%14.0%8.8%11.0%15.0%
Dividend payout0.0%0.0%0.0%0.0%0.0%8.0%0.0%0.0%

Jfl Life Sciences debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown. It borrowed much more last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers pay faster than they did in FY24, which frees up the company's money.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
0204060Net worth, FY19: 5.4 ₹ cr5.4Borrowings, FY19: 8 ₹ cr8FY19Net worth, FY20: 5.4 ₹ cr5.4Borrowings, FY20: 9 ₹ cr9FY20Net worth, FY21: 6.5 ₹ cr6.5Borrowings, FY21: 17 ₹ cr17FY21Net worth, FY22: 11 ₹ cr11Borrowings, FY22: 16 ₹ cr16FY22Net worth, FY23: 32 ₹ cr32Borrowings, FY23: 7 ₹ cr7FY23Net worth, FY24: 36 ₹ cr36Borrowings, FY24: 6 ₹ cr6FY24Net worth, FY25: 39.5 ₹ cr39.5Borrowings, FY25: 10.6 ₹ cr10.6FY25Net worth, FY26: 45.9 ₹ cr45.9Borrowings, FY26: 21.7 ₹ cr21.7FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-10-50510Cash from the business, FY19: -3 ₹ cr-3Net profit, FY19: 0 ₹ cr0FY19Cash from the business, FY20: 3 ₹ cr3Net profit, FY20: 0 ₹ cr0FY20Cash from the business, FY21: -6 ₹ cr-6Net profit, FY21: 1 ₹ cr1FY21Cash from the business, FY22: 2 ₹ cr2Net profit, FY22: 3 ₹ cr3FY22Cash from the business, FY23: -9 ₹ cr-9Net profit, FY23: 3 ₹ cr3FY23Cash from the business, FY24: 8 ₹ cr8Net profit, FY24: 3 ₹ cr3FY24Cash from the business, FY25: -3.5 ₹ cr-3.5Net profit, FY25: 4.2 ₹ cr4.2FY25Cash from the business, FY26: -4.3 ₹ cr-4.3Net profit, FY26: 6.4 ₹ cr6.4FY26

Bars below the line are cash going out.

Jfl Life Sciences balance sheet

At each 31 March · ₹ crore

₹ crore
FY19FY20FY21FY22FY23FY24FY25FY26
Equity capital0.420.420.50811113333
Reserves556321256.4612.87
Net worth5.425.426.5011323639.4645.87
Borrowings8917167610.5921.73
Other liabilities2.589.585.5021101521.8638.65
Total liabilities16242948495771.91106.25
Fixed assets256771212.2414.54
Capital work in progress00000000
Investments00000000
Other assets14192341424559.6791.71
Receivables······34.9553.26
Inventory······23.2434.55
Cash······0.061.46
Trade payables······17.7629.28

Jfl Life Sciences cash flow

₹ crore

₹ crore
FY19FY20FY21FY22FY23FY24FY25FY26
Cash from operations-33-62-98-3.53-4.34
Cash from investing-1-3-2-11-6-0.01-3.94
Cash from financing407-18-23.549.10
Net cash flow00-100000.82
Capital spending······0.403.38

Working capital

Days

Days
FY19FY20FY21FY22FY23FY24FY25FY26
Debtor days111153132215192197155148
Inventory days215272212130149128110
Days payable181225821876929893
Cash conversion cycle11583146208246254186165
Working capital days62774117221181124103

Jfl Life Sciences peers and competitors

Listed SME companies in the same industry

By sales, Jfl Life Sciences is number 9 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Zenith Drugs6817.21713.97.1%0.75
Mono Pharmacare1644.61660.42.4%1.79
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences396.11316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
KRM Ayurveda57328.61022030.0%0.00
Sotac Pharmaceuticals10017.31015.817.7%0.64
Median of the 10 others12721.31295.412.7%0.57

Jfl Life Sciences shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.

Promoters
67.47%
0.00 pts since Sep 24
Foreign investors (FIIs)
0.00%
at Mar 25; not in the latest pattern
Indian institutions (DIIs)
0.00%
at Mar 25; not in the latest pattern
HNIs (over ₹2 lakh each)
11.43%
+8.27 pts since Mar 25
Small holders (up to ₹2 lakh)
16.99%
-8.61 pts since Mar 25
Companies and others
4.11%
+0.34 pts since Mar 25
Number of shareholders
904
966 in Sep 24

Jfl Life Sciences shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Sep 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Promoters67.47%67.47%67.47%67.47%67.47%67.47%67.47%67.47%
Foreign investors (FIIs)-0.00%------
Indian institutions (DIIs)-0.00%------
HNIs (over ₹2 lakh each)-3.16%10.67%10.64%10.41%10.43%10.47%11.43%
Small holders (up to ₹2 lakh)-25.60%18.28%18.24%18.13%18.06%17.84%16.99%
Companies and others-3.77%3.58%3.65%3.99%4.04%4.22%4.11%
Number of shareholders9669971,008998991971943904

The named holders are at 30 Sept 2026, beside 30 June 2026, each under the group the pattern files them in.

Jfl Life Sciences latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • Shareholding, 30 Sept 2026: promoters unchanged at 67.47%.

Jfl Life Sciences annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Jfl Life Sciences share split, bonus and dividends

From the corporate actions the company announces on the exchange

  • Rights issueRIGHTS 1:1 @ PREMIUM RS 0/-ex-date 10 March 2026
  • Bonus issueBONUS 2:1ex-date 24 Sept 2024
  • DividendDIVIDEND - RE 0.25 PER SHAREex-date 13 Sept 2024
Checks we ran on Jfl Life Sciences' data · 10

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • !The two halves of FY26 as reported add up to sales of ₹104.55 cr, the full year to ₹131.38 cr; one of the filings may have been restated.
  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (3,29,95,323 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • !The two half-years of FY26 add up to ₹104.5 cr of sales against ₹131.4 cr for the full year, so the half-years of FY26 are held back.
  • !Earnings per share changes basis between FY21 (₹1.50) and FY22 (₹0.59) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
  • ✓Revenue and profit are reported for every year shown, FY19 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Jfl Life Sciences

What does Jfl Life Sciences do?

Jfl Life Sciences is an SME company listed on NSE Emerge, in pharmaceuticals & biotechnology.

What is the share price of Jfl Life Sciences?

₹11.8 at the close on 6 Nov 2026, from the exchange's daily figures.

What is the market cap of Jfl Life Sciences?

₹39 cr at the close on 6 Nov 2026, on 3,29,95,323 shares.

What is the P/E of Jfl Life Sciences?

6.1 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).

What are Jfl Life Sciences' revenue and profit?

Revenue ₹131 cr and profit after tax ₹6 cr in FY26.

Who are the promoters of Jfl Life Sciences?

The promoter group; promoters held 67.47% at 30 Sept 2026.

What is Jfl Life Sciences' website?

www.jfllifesciences.com

More SME companies like Jfl Life Sciences

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2022 →

Built from 21 exchange announcements, 8 shareholding patterns and 8 years of reported results. Every figure carries its source; where the documents are silent, the page says so.